Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Maximizing Panfacial Aesthetic Outcomes: Findings and Recommendations From the HARMONY Study.

Kaminer MS, Cohen JL, Shamban A, Werschler WP, Shumate GT, Drinkwater A, Gallagher CJ.

Dermatol Surg. 2019 Dec 11. doi: 10.1097/DSS.0000000000002271. [Epub ahead of print]

PMID:
31834076
2.

Racial and Ethnic Differences in Self-Assessed Facial Aging in Women: Results From a Multinational Study.

Alexis AF, Grimes P, Boyd C, Downie J, Drinkwater A, Garcia JK, Gallagher CJ.

Dermatol Surg. 2019 Dec;45(12):1635-1648. doi: 10.1097/DSS.0000000000002237.

PMID:
31702594
3.

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).

Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, Liu Y, Rubio RG, Cohen JL, Ho S, Cox SE, Soderberg J, Swift A, Borsuk D, Papanastasiou V, Shamban A, Simzar S, Bertucci V, Waller B, Boyd C, Katz M, Churchill L, Smith S, Burgess C, Dhir K, Draelos Z, Draelos M, Rosen N, Muhn C, Bhatia AC, Desai S, Hsu TS, Kelly CT, Brazell BM, Downie J, Katz B, Woody M, Lupo M, Souyoul S, Mariwalla K, Eviatar J, Werschler WP, Schade S, Glogau RG, Jones D, Black JM, Wesley N, Kaufman-Janette J, Schlessinger J, Hall J, Perillo S, Dover J, Morton L, Solish N, Monheit G, Essig H, Yoelin S, Yoelin S; SAKURA 1 and SAKURA 2 Investigator Group; SAKURA 1 and SAKURA 2 Investigator Group includes the following.

Plast Reconstr Surg. 2020 Jan;145(1):45-58. doi: 10.1097/PRS.0000000000006327.

PMID:
31609882
4.

Impact of Smoking and Alcohol Use on Facial Aging in Women: Results of a Large Multinational, Multiracial, Cross-sectional Survey.

Goodman GD, Kaufman J, Day D, Weiss R, Kawata AK, Garcia JK, Santangelo S, Gallagher CJ.

J Clin Aesthet Dermatol. 2019 Aug;12(8):28-39. Epub 2019 Aug 1.

5.

Myths and Knowledge Gaps in the Aesthetic Treatment of Patients With Skin of Color

Alexis AF, Few J, Callender VD, Grimes P, Downie J, Boyd C, Gallagher CJ.

J Drugs Dermatol. 2019 Jul 1;18(7):616-622.

PMID:
31329382
6.

Lip and Perioral Enhancement With Hyaluronic Acid Dermal Fillers in Individuals With Skin of Color.

Taylor SC, Downie JB, Shamban A, Few J, Weichman BM, Schumacher A, Gallagher CJ.

Dermatol Surg. 2019 Jul;45(7):959-967. doi: 10.1097/DSS.0000000000001842.

PMID:
30789512
7.

Relationship Between Midface Volume Deficits and the Appearance of Tear Troughs and Nasolabial Folds.

Glaser DA, Lambros V, Kolodziejczyk J, Magyar A, Dorries K, Gallagher CJ.

Dermatol Surg. 2018 Dec;44(12):1547-1554. doi: 10.1097/DSS.0000000000001684.

PMID:
30379685
8.

Aesthetic Treatment Positively Impacts Social Perception: Analysis of Subjects From the HARMONY Study.

Dayan S, Rivkin A, Sykes JM, Teller CF, Weinkle SH, Shumate GT, Gallagher CJ.

Aesthet Surg J. 2019 Nov 13;39(12):1380-1389. doi: 10.1093/asj/sjy239.

PMID:
30239596
9.

Personal (Self) Perceptions of Submental Fat Among Adults in the United States.

Baumann L, Shridharani SM, Humphrey S, Gallagher CJ.

Dermatol Surg. 2019 Jan;45(1):124-130. doi: 10.1097/DSS.0000000000001648.

10.

Improving access to specialized care for first-episode psychosis: an ecological model.

Moe AM, Rubinstein EB, Gallagher CJ, Weiss DM, Stewart A, Breitborde NJ.

Risk Manag Healthc Policy. 2018 Aug 30;11:127-138. doi: 10.2147/RMHP.S131833. eCollection 2018. Review.

11.

Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results From a Post hoc Analysis.

Dover JS, Shridharani SM, Bloom JD, Somogyi C, Gallagher CJ.

Dermatol Surg. 2018 Nov;44(11):1477-1479. doi: 10.1097/DSS.0000000000001484. No abstract available.

12.

Schizophrenia, narrative, and neurocognition: The utility of life-stories in understanding social problem-solving skills.

Moe AM, Breitborde NJK, Bourassa KJ, Gallagher CJ, Shakeel MK, Docherty NM.

Psychiatr Rehabil J. 2018 Jun;41(2):83-91. doi: 10.1037/prj0000286. Epub 2018 Jan 22.

PMID:
29355334
13.

The Male Aesthetic Patient: Facial Anatomy, Concepts of Attractiveness, and Treatment Patterns.

Keaney TC, Anolik R, Braz A, Eidelman M, Eviatar JA, Green JB, Jones DH, Narurkar VA, Rossi AM, Gallagher CJ.

J Drugs Dermatol. 2018 Jan 1;17(1):19-28. Review.

PMID:
29320584
14.

Impact of Comprehensive, Minimally Invasive, Multimodal Aesthetic Treatment on Satisfaction With Facial Appearance: The HARMONY Study.

Weinkle SH, Werschler WP, Teller CF, Sykes JM, Shamban A, Rivkin A, Narurkar VA, Kaminer MS, Dayan S, Cohen JL, Gallagher CJ.

Aesthet Surg J. 2018 Apr 6;38(5):540-556. doi: 10.1093/asj/sjx179.

PMID:
29244069
15.

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.

Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, Gourley C, Romero I, Gonzalez-Martin A, Feeney M, Bessette P, Hall M, Weberpals JI, Hall G, Lau SK, Gauthier P, Fung-Kee-Fung M, Eisenhauer EA, Winch C, Tu D, MacKay HJ.

Ann Oncol. 2018 Feb 1;29(2):431-438. doi: 10.1093/annonc/mdx754.

16.

Signs of Facial Aging in Men in a Diverse, Multinational Study: Timing and Preventive Behaviors.

Rossi AM, Eviatar J, Green JB, Anolik R, Eidelman M, Keaney TC, Narurkar V, Jones D, Kolodziejczyk J, Drinkwater A, Gallagher CJ.

Dermatol Surg. 2017 Nov;43 Suppl 2:S210-S220. doi: 10.1097/DSS.0000000000001293.

PMID:
29064988
17.

Reduced total serum bilirubin levels are associated with ulcerative colitis.

Schieffer KM, Bruffy SM, Rauscher R, Koltun WA, Yochum GS, Gallagher CJ.

PLoS One. 2017 Jun 8;12(6):e0179267. doi: 10.1371/journal.pone.0179267. eCollection 2017.

18.

Comparison of self-reported signs of facial ageing among Caucasian women in Australia versus those in the USA, the UK and Canada.

Goodman GJ, Armour KS, Kolodziejczyk JK, Santangelo S, Gallagher CJ.

Australas J Dermatol. 2018 May;59(2):108-117. doi: 10.1111/ajd.12637. Epub 2017 Apr 10.

19.

Facial Treatment Preferences Among Aesthetically Oriented Men.

Jagdeo J, Keaney T, Narurkar V, Kolodziejczyk J, Gallagher CJ.

Dermatol Surg. 2016 Oct;42(10):1155-63. doi: 10.1097/DSS.0000000000000876.

PMID:
27661428
20.

A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study.

Narurkar VA, Cohen JL, Dayan S, Kaminer MS, Rivkin A, Shamban A, Sykes JM, Teller CF, Weinkle SH, Werschler WP, Drinkwater A, Pucci ML, Gallagher CJ.

Dermatol Surg. 2016 May;42 Suppl 2:S177-91. doi: 10.1097/DSS.0000000000000743. Erratum in: Dermatol Surg. 2016 Nov;42(11):1311.

PMID:
27128246
21.

Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials.

Baumann L, Dayan S, Connolly S, Silverberg N, Lei X, Drinkwater A, Gallagher CJ.

Dermatol Surg. 2016 May;42(5):598-607. doi: 10.1097/DSS.0000000000000757.

22.

OnabotulinumtoxinA for Treatment of Moderate to Severe Crow's Feet Lines: A Review.

Carruthers A, Bruce S, Cox SE, Kane MA, Lee E, Gallagher CJ.

Aesthet Surg J. 2016 May;36(5):591-7. doi: 10.1093/asj/sjw025. Epub 2016 Mar 15. Review.

PMID:
26979457
23.

Idea density in the life-stories of people with schizophrenia: Associations with narrative qualities and psychiatric symptoms.

Moe AM, Breitborde NJ, Shakeel MK, Gallagher CJ, Docherty NM.

Schizophr Res. 2016 Apr;172(1-3):201-5. doi: 10.1016/j.schres.2016.02.016. Epub 2016 Feb 28.

PMID:
26925799
24.

The Efficacy and Safety of Topical Dapsone Gel, 5% for the Treatment of Acne Vulgaris in Adult Females With Skin of Color.

Alexis AF, Burgess C, Callender VD, Herzog JL, Roberts WE, Schweiger ES, Stockton TC, Gallagher CJ.

J Drugs Dermatol. 2016 Feb;15(2):197-204.

PMID:
26885788
25.

HYC-24L Demonstrates Greater Effectiveness With Less Pain Than CPM-22.5 for Treatment of Perioral Lines in a Randomized Controlled Trial.

Butterwick K, Marmur E, Narurkar V, Cox SE, Joseph JH, Sadick NS, Tedaldi R, Wheeler S, Kolodziejczyk JK, Gallagher CJ.

Dermatol Surg. 2015 Dec;41(12):1351-60. doi: 10.1097/DSS.0000000000000576.

PMID:
26606435
26.

No Association Between Vitamin D Intake, VDR Polymorphisms, and Colorectal Cancer in a Population-Based Case-Control Study.

Ashmore JH, Gallagher CJ, Lesko SM, Muscat JE, Hartman TJ, Lazarus P.

Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1635-7. doi: 10.1158/1055-9965.EPI-15-0284. Epub 2015 Jul 29.

27.

Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.

Rivers JK, Bertucci V, McGillivray W, Muhn C, Rosen N, Solish N, Weichman BM, Wheeler S, Daniels SR, Gallagher CJ.

Dermatol Surg. 2015 Aug;41(8):950-9. doi: 10.1097/DSS.0000000000000424.

PMID:
26218728
28.

Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.

Carruthers A, Sadick N, Brandt F, Trindade de Almeida AR, Fagien S, Goodman GJ, Raspaldo H, Smith K, Darmody S, Gallagher CJ, Street J, Romagnano L.

Dermatol Surg. 2015 Jun;41(6):693-701. doi: 10.1097/DSS.0000000000000340.

PMID:
25973559
29.

Heterogeneity of crow's feet line patterns in clinical trial subjects.

Kane MA, Cox SE, Jones D, Lei X, Gallagher CJ.

Dermatol Surg. 2015 Apr;41(4):447-56. doi: 10.1097/DSS.0000000000000336.

PMID:
25789814
30.

Comparative efficacy and tolerability of dapsone 5% gel in adult versus adolescent females with acne vulgaris.

Del Rosso JQ, Kircik L, Gallagher CJ.

J Clin Aesthet Dermatol. 2015 Jan;8(1):31-7.

31.

Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments.

Trindade de Almeida A, Carruthers J, Cox SE, Goldman MP, Wheeler S, Gallagher CJ.

Dermatol Surg. 2015 Jan;41 Suppl 1:S19-28. doi: 10.1097/DSS.0000000000000275.

PMID:
25548841
32.

A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis.

Yoelin SG, Fagien S, Cox SE, Davis PG, Campo A, Caulkins CA, Gallagher CJ.

Dermatol Surg. 2014 Oct;40(10):1118-24. doi: 10.1097/01.DSS.0000452658.83001.d9.

PMID:
25229783
33.

NNK reduction pathway gene polymorphisms and risk of lung cancer.

Modesto JL, Hull A, Angstadt AY, Berg A, Gallagher CJ, Lazarus P, Muscat JE.

Mol Carcinog. 2015 Jun;54 Suppl 1:E94-E102. doi: 10.1002/mc.22187. Epub 2014 Jun 29.

34.

The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.

Angstadt AY, Hartman TJ, Lesko SM, Muscat JE, Zhu J, Gallagher CJ, Lazarus P.

Genes Chromosomes Cancer. 2014 Jun;53(6):454-66.

35.

Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia.

Marsh WA, Monroe DM, Brin MF, Gallagher CJ.

BMC Neurol. 2014 Apr 27;14:91. doi: 10.1186/1471-2377-14-91. Review.

36.

The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.

Banegas RA, Farache F, Rancati A, Chain M, Gallagher CJ, Chapman MA, Caulkins CA.

Aesthet Surg J. 2013 Sep 1;33(7):1039-45. doi: 10.1177/1090820X13503475. Epub 2013 Aug 29.

PMID:
23990584
37.

Association of dietary and supplemental folate intake and polymorphisms in three FOCM pathway genes with colorectal cancer in a population-based case-control study.

Ashmore JH, Lesko SM, Muscat JE, Gallagher CJ, Berg AS, Miller PE, Hartman TJ, Lazarus P.

Genes Chromosomes Cancer. 2013 Oct;52(10):945-53. doi: 10.1002/gcc.22089. Epub 2013 Jul 26.

PMID:
23893618
38.

Multicentre, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.

Fulford-Smith A, Gallagher CJ, Brin MF.

Dermatol Surg. 2013 Jul;39(7):1118-9. doi: 10.1111/dsu.12101. Epub 2013 May 31. No abstract available.

PMID:
23725480
39.

The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk.

Angstadt AY, Berg A, Zhu J, Miller P, Hartman TJ, Lesko SM, Muscat JE, Lazarus P, Gallagher CJ.

Cancer. 2013 Jul 1;119(13):2477-85. doi: 10.1002/cncr.28009. Epub 2013 Apr 10.

40.

Vitamin D: do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe.

Brouwer-Brolsma EM, Bischoff-Ferrari HA, Bouillon R, Feskens EJ, Gallagher CJ, Hypponen E, Llewellyn DJ, Stoecklin E, Dierkes J, Kies AK, Kok FJ, Lamberg-Allardt C, Moser U, Pilz S, Saris WH, van Schoor NM, Weber P, Witkamp R, Zittermann A, de Groot LC.

Osteoporos Int. 2013 May;24(5):1567-77. doi: 10.1007/s00198-012-2231-3. Epub 2012 Dec 11.

PMID:
23229471
41.

Immunogenicity of botulinum toxins.

Naumann M, Boo LM, Ackerman AH, Gallagher CJ.

J Neural Transm (Vienna). 2013 Feb;120(2):275-90. doi: 10.1007/s00702-012-0893-9. Epub 2012 Sep 25. Review.

42.

Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.

Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA.

Int J Gynecol Cancer. 2012 May;22(4):566-72. doi: 10.1097/IGC.0b013e318247727f.

PMID:
22426404
43.

A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium.

McKay JD, Truong T, Gaborieau V, Chabrier A, Chuang SC, Byrnes G, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Holcatova I, Janout V, Foretova L, Lagiou P, Trichopoulos D, Benhamou S, Bouchardy C, Ahrens W, Merletti F, Richiardi L, Talamini R, Barzan L, Kjaerheim K, Macfarlane GJ, Macfarlane TV, Simonato L, Canova C, Agudo A, Castellsagué X, Lowry R, Conway DI, McKinney PA, Healy CM, Toner ME, Znaor A, Curado MP, Koifman S, Menezes A, Wünsch-Filho V, Neto JE, Garrote LF, Boccia S, Cadoni G, Arzani D, Olshan AF, Weissler MC, Funkhouser WK, Luo J, Lubiński J, Trubicka J, Lener M, Oszutowska D, Schwartz SM, Chen C, Fish S, Doody DR, Muscat JE, Lazarus P, Gallagher CJ, Chang SC, Zhang ZF, Wei Q, Sturgis EM, Wang LE, Franceschi S, Herrero R, Kelsey KT, McClean MD, Marsit CJ, Nelson HH, Romkes M, Buch S, Nukui T, Zhong S, Lacko M, Manni JJ, Peters WH, Hung RJ, McLaughlin J, Vatten L, Njølstad I, Goodman GE, Field JK, Liloglou T, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, González CA, Quirós JR, Martínez C, Navarro C, Ardanaz E, Larrañaga N, Khaw KT, Key T, Bueno-de-Mesquita HB, Peeters PH, Trichopoulou A, Linseisen J, Boeing H, Hallmans G, Overvad K, Tjønneland A, Kumle M, Riboli E, Välk K, Vooder T, Metspalu A, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Blanché H, Gut IG, Galan P, Heath S, Hashibe M, Hayes RB, Boffetta P, Lathrop M, Brennan P.

PLoS Genet. 2011 Mar;7(3):e1001333. doi: 10.1371/journal.pgen.1001333. Epub 2011 Mar 17. Erratum in: PLoS Genet. 2011 Apr;7(4). doi: 10.1371/annotation/9952526f-2f1f-47f3-af0f-1a7cf6f0abc1. Voodern, Tõnu [corrected to Vooder, Tõnu].

44.

Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Chen G, Giambrone NE Jr, Dluzen DF, Muscat JE, Berg A, Gallagher CJ, Lazarus P.

Cancer Res. 2010 Oct 1;70(19):7543-52. doi: 10.1158/0008-5472.CAN-09-4582. Epub 2010 Sep 28.

45.

Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population.

Jones NR, Spratt TE, Berg AS, Muscat JE, Lazarus P, Gallagher CJ.

Cancer Epidemiol. 2011 Apr;35(2):175-81. doi: 10.1016/j.canep.2010.08.007. Epub 2010 Sep 21.

46.

Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity.

Gallagher CJ, Balliet RM, Sun D, Chen G, Lazarus P.

Drug Metab Dispos. 2010 Dec;38(12):2204-9. doi: 10.1124/dmd.110.035345. Epub 2010 Sep 1.

47.

FOXO3 encodes a carcinogen-activated transcription factor frequently deleted in early-stage lung adenocarcinoma.

Mikse OR, Blake DC Jr, Jones NR, Sun YW, Amin S, Gallagher CJ, Lazarus P, Weisz J, Herzog CR.

Cancer Res. 2010 Aug 1;70(15):6205-15. doi: 10.1158/0008-5472.CAN-09-4008. Epub 2010 Jul 14.

48.

The current status of simulation in the maintenance of certification in anesthesia.

Gallagher CJ, Tan JM.

Int Anesthesiol Clin. 2010 Summer;48(3):83-99. doi: 10.1097/AIA.0b013e3181eace5e. No abstract available.

PMID:
20616639
49.

Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.

Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Evans TR.

Breast Cancer Res Treat. 2010 Aug;122(3):787-94. doi: 10.1007/s10549-010-0989-6. Epub 2010 Jun 18.

PMID:
20559708
50.

Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium.

Truong T, Hung RJ, Amos CI, Wu X, Bickeböller H, Rosenberger A, Sauter W, Illig T, Wichmann HE, Risch A, Dienemann H, Kaaks R, Yang P, Jiang R, Wiencke JK, Wrensch M, Hansen H, Kelsey KT, Matsuo K, Tajima K, Schwartz AG, Wenzlaff A, Seow A, Ying C, Staratschek-Jox A, Nürnberg P, Stoelben E, Wolf J, Lazarus P, Muscat JE, Gallagher CJ, Zienolddiny S, Haugen A, van der Heijden HF, Kiemeney LA, Isla D, Mayordomo JI, Rafnar T, Stefansson K, Zhang ZF, Chang SC, Kim JH, Hong YC, Duell EJ, Andrew AS, Lejbkowicz F, Rennert G, Müller H, Brenner H, Le Marchand L, Benhamou S, Bouchardy C, Teare MD, Xue X, McLaughlin J, Liu G, McKay JD, Brennan P, Spitz MR.

J Natl Cancer Inst. 2010 Jul 7;102(13):959-71. doi: 10.1093/jnci/djq178. Epub 2010 Jun 14.

Supplemental Content

Loading ...
Support Center